Koyfin Home > Directory > Health Care > Kindred Biosciences > Gross Margin

Kindred Biosciences Gross Margin Chart (KIN)

Kindred Biosciences annual/quarterly Gross Margin from 2018 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Kindred Biosciences Gross Margin for the quarter ending June 06, 2020 was $58m a -50.37% decrease of -29m year over year
  • Kindred Biosciences Gross Margin for the last 12 months ending June 06, 2020 was $-7m a 1,265.39% decrease of -93m year over year
  • Kindred Biosciences Annual Gross Margin for 2019 was $86m a 3.12% increase of 3m from 2018
  • Kindred Biosciences Annual Gross Margin for 2018 was $84m
Other Margins & Efficiency Metrics:
  • Kindred Biosciences Return on Capital % for the quarter ending September 09, 2018 was -30.78 a 8.89% decrease of -2.73 year over year
  • Kindred Biosciences Return on Equity % for the quarter ending September 09, 2018 was -47.37 a 7.47% decrease of -3.54 year over year
View Chart On Koyfin

Quarterly KIN Gross Margin Data

06/2020$58m
03/2020$-493m
12/2019$87m
09/2019$87m
06/2019$86m
03/2019$82m
12/2018$84m
09/2018$83m

Annual KIN Gross Margin Data

2019$86m
2018$84m